For example, anti-angiogenic drugs targeting tumor vasculature and VEGF, such as bevacizumab, in combination with chemotherapy, are considered a preferred strategy for normalizing tumor vasculature and reversing tumor drug resistance. The gene discussed is VEGFA; the disease is neoplasm.